[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA38085B1 - Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer - Google Patents

Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Info

Publication number
MA38085B1
MA38085B1 MA38085A MA38085A MA38085B1 MA 38085 B1 MA38085 B1 MA 38085B1 MA 38085 A MA38085 A MA 38085A MA 38085 A MA38085 A MA 38085A MA 38085 B1 MA38085 B1 MA 38085B1
Authority
MA
Morocco
Prior art keywords
production
cancer
compounds
treatment
new process
Prior art date
Application number
MA38085A
Other languages
English (en)
Other versions
MA38085A1 (fr
Inventor
C Gregory Sowell
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA38085A1 publication Critical patent/MA38085A1/fr
Publication of MA38085B1 publication Critical patent/MA38085B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un procédé pour la production d'un composé de formule i. Ledit composé de formule i est un inhibiteur de mek et peut ainsi être utilisé pour traiter le cancer.
MA38085A 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer MA38085B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (fr) 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Publications (2)

Publication Number Publication Date
MA38085A1 MA38085A1 (fr) 2018-08-31
MA38085B1 true MA38085B1 (fr) 2018-11-30

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38085A MA38085B1 (fr) 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Country Status (31)

Country Link
US (4) US9771347B2 (fr)
EP (1) EP2909188B1 (fr)
JP (2) JP6300042B2 (fr)
KR (1) KR102204520B1 (fr)
CN (2) CN108948043B (fr)
AU (1) AU2013328929B2 (fr)
BR (1) BR112015008113B1 (fr)
CA (1) CA2889466C (fr)
CL (1) CL2015000926A1 (fr)
CR (2) CR20200237A (fr)
EA (1) EA030613B1 (fr)
ES (1) ES2671502T3 (fr)
GE (1) GEP201706690B (fr)
HK (2) HK1213567A1 (fr)
HR (1) HRP20180670T1 (fr)
IL (1) IL238116B (fr)
IN (1) IN2015DN03928A (fr)
MA (1) MA38085B1 (fr)
MX (2) MX2015004660A (fr)
MY (1) MY186549A (fr)
NZ (1) NZ706723A (fr)
PE (3) PE20191818A1 (fr)
PH (1) PH12015500785B1 (fr)
PL (1) PL2909188T3 (fr)
SA (1) SA515360271B1 (fr)
SG (1) SG11201502795VA (fr)
SI (1) SI2909188T1 (fr)
TR (1) TR201807861T4 (fr)
UA (1) UA115455C2 (fr)
WO (1) WO2014059422A1 (fr)
ZA (1) ZA201502349B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38085B1 (fr) 2012-10-12 2018-11-30 Exelixis Inc Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
IL303352A (en) 2015-06-30 2023-08-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
WO2018031865A1 (fr) 2016-08-12 2018-02-15 Genentech, Inc. Polythérapie avec un inhibiteur de mek, un inhibiteur de l'axe pd-1 et un inhibiteur de vegf
CN109862917A (zh) 2016-09-29 2019-06-07 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
WO2020187674A1 (fr) 2019-03-15 2020-09-24 Sandoz Ag Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin
JP2024509269A (ja) 2021-03-09 2024-02-29 ジェネンテック， インコーポレイテッド 脳がんの治療における使用のためのベルバラフェニブ
CN117561062A (zh) 2021-04-06 2024-02-13 基因泰克公司 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CA2186947A1 (fr) 1994-04-01 1995-10-12 Kazuo Ueda Derive d'oxime et bactericide le contenant en tant qu'ingredient actif
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (fr) 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
WO1999001426A1 (fr) 1997-07-01 1999-01-14 Warner-Lambert Company Derives d'acide benzhydroxamique phenylamino 4-bromo ou 4-iodo et utilisation de ces derniers en tant qu'inhibiteurs de mek
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501277A (en) * 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
DE69928568T2 (de) 1998-12-22 2006-07-27 Warner-Lambert Co. Llc Chemotheriapie mit einem antimitotischen mittel und einem mek inhibitor
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
CA2358438A1 (fr) 1999-01-07 2000-07-13 David Thomas Dudley Methode antivirale utilisant des inhibiteurs de mek
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
US6440966B1 (en) 1999-01-13 2002-08-27 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
GEP20032999B (en) 1999-01-13 2003-06-25 Warner Lambert Co 1-Heterocycle Substituted Diarylamines
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
CA2348236A1 (fr) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
ES2247859T3 (es) 1999-01-13 2006-03-01 Warner-Lambert Company Llc Benzoheterociclos y su uso como inhibidores de mek.
JP2003504398A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性疼痛の治療方法
CA2377100A1 (fr) 1999-07-16 2001-01-25 Warner-Lambert Company Methode de traitement de la douleur chronique utilisant des inhibiteurs mek
IL147618A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
NZ515567A (en) 1999-07-16 2004-03-26 Warner Lambert Co Method for treating chronic pain using MEK inhibitors
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
CA2403017A1 (fr) 2000-03-15 2001-09-20 Warner-Lambert Company Diarylamines a substitution 5-amide, utilises en tant qu'inhibiteur de kinases erk mitogenes mek
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
KR100773621B1 (ko) 2000-07-19 2007-11-05 워너-램버트 캄파니 엘엘씨 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르
EP1313694A1 (fr) * 2000-08-25 2003-05-28 Warner-Lambert Company Procede de fabrication d'acides n-aryle-anthraniliques et de leurs derives
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
CZ2004524A3 (cs) 2001-10-31 2004-07-14 Pfizer Products Inc. Agonisté nikotinového acetylcholinového receptoru v léčbě syndromu neklidných nohou
EP1467968A1 (fr) 2002-01-23 2004-10-20 Warner-Lambert Company LLC Esters hydroxamates d'acide n-(phenyl substitue en 4)-anthranilique
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
MXPA04008893A (es) 2002-03-13 2005-06-20 Array Biopharma Inc Derivados de bencimidazol n3 alquilados como inhibidores de mek.
US20030216460A1 (en) 2002-03-13 2003-11-20 Wallace Eli M. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003238915B2 (en) 2002-06-11 2008-02-21 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (fr) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Association d'un inhibiteur de cible mammalienne de rapamycine (mtor) et d'un inhibiteur de la tyrosine kinase aux fins du de traitement de neoplasmes
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
RU2357957C2 (ru) 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
JP2007516161A (ja) 2003-06-20 2007-06-21 セルテック アール アンド ディ リミテッド キナーゼ阻害剤としてのチエノピリドン誘導体
WO2005000818A1 (fr) 2003-06-27 2005-01-06 Warner-Lambert Company Llc Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
RS51861B (en) 2003-11-19 2012-02-29 Array Biopharma Inc. HETEROCYCLIC MEK INHIBITORS
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN100509808C (zh) 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 新型噻唑衍生物
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
WO2006061712A2 (fr) 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN104892582B (zh) 2005-10-07 2019-09-27 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
US7999006B2 (en) * 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
MA38085B1 (fr) 2012-10-12 2018-11-30 Exelixis Inc Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
WO2015118793A1 (fr) 2014-02-07 2015-08-13 住友化学株式会社 Procédé de production de (r)-1,1,3-triméthyl-4-aminoindane
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
KR20150067339A (ko) 2015-06-17
MY186549A (en) 2021-07-26
US9771347B2 (en) 2017-09-26
JP2015533175A (ja) 2015-11-19
US20190185447A1 (en) 2019-06-20
JP6300042B2 (ja) 2018-03-28
PH12015500785A1 (en) 2015-06-15
EP2909188A1 (fr) 2015-08-26
IN2015DN03928A (fr) 2015-10-02
CN104837826A (zh) 2015-08-12
WO2014059422A1 (fr) 2014-04-17
HRP20180670T1 (hr) 2018-07-13
BR112015008113B1 (pt) 2022-05-24
AU2013328929A1 (en) 2015-04-30
BR112015008113A2 (pt) 2017-07-04
GEP201706690B (en) 2017-06-26
PH12015500785B1 (en) 2015-06-15
MX2015004660A (es) 2015-08-07
HK1213878A1 (zh) 2016-07-15
CR20150245A (es) 2015-11-19
CA2889466A1 (fr) 2014-04-17
US20200392104A1 (en) 2020-12-17
TR201807861T4 (tr) 2018-06-21
IL238116B (en) 2018-06-28
SA515360271B1 (ar) 2016-05-19
PE20191818A1 (es) 2019-12-27
PE20200387A1 (es) 2020-02-24
PE20151494A1 (es) 2015-11-06
HK1213567A1 (zh) 2016-07-08
SG11201502795VA (en) 2015-05-28
MA38085A1 (fr) 2018-08-31
CN108948043B (zh) 2021-05-04
ES2671502T3 (es) 2018-06-06
CN108948043A (zh) 2018-12-07
AU2013328929B2 (en) 2018-01-04
JP2018052973A (ja) 2018-04-05
EA030613B1 (ru) 2018-08-31
CR20200237A (es) 2020-07-26
CA2889466C (fr) 2021-09-14
KR102204520B1 (ko) 2021-01-20
NZ706723A (en) 2018-07-27
US10239858B2 (en) 2019-03-26
EA201590700A1 (ru) 2015-09-30
US11414396B2 (en) 2022-08-16
MX2020005533A (es) 2020-10-12
UA115455C2 (uk) 2017-11-10
CN104837826B (zh) 2018-07-27
ZA201502349B (en) 2019-12-18
US10793541B2 (en) 2020-10-06
PL2909188T3 (pl) 2018-08-31
SI2909188T1 (en) 2018-07-31
EP2909188B1 (fr) 2018-03-07
CL2015000926A1 (es) 2015-08-28
US20150210668A1 (en) 2015-07-30
US20170349569A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
MA38085A1 (fr) Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
CY1122272T1 (el) ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
PH12018501410A1 (en) Therapeutically active compounds and their method of use
EA201891553A1 (ru) Ингибиторы syk
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
MA35432B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
MA40076A (fr) Inhibiteurs de syk
EA201290909A1 (ru) Химические соединения
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
NZ715747A (en) Syk inhibitors
EA201691727A1 (ru) Фосфонатные соединения для лечения опосредованных комплементом нарушений
PH12016500225A1 (en) Novel quinoline-substituted compound
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA39048B1 (fr) Nouveaux inhibiteurs de la dgat2
EA201391591A1 (ru) Лечение множественной миеломы
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
MA38307A1 (fr) 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale
MA39110B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39109B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
PL418655A1 (pl) Kwas 3,7,11,15-tetrametylo-3-winyloheksadekanowy oraz sposób otrzymywania kwasu 3,7,11,15-tetrametylo-3-winyloheksadekanowego
MA39062B1 (fr) Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine